Research and Clinical Trials
The research themes of the Women’s Cancer Program include:
Inherited and acquired genetic factors that contribute to breast and/or gynecologic cancers: identify modifiers of penetrance and mechanisms that influence survival.
Cancer etiology, biology, and metastasis: investigate the cell or origin, tumor microenvironment, epithelial-mesenchymal transition, and metabolomics.
Personalized therapeutic approaches: develop molecular and epidemiologic risk profiles to direct individualized therapy.
As part of its commitment to research, Cedars-Sinai provides extensive laboratory facilities with 5 labs devoted to the Women’s Cancer Program. Each lab has its own faculty principal investigator in basic science. Within these labs are 45 scientists and staff focused on conducting the latest in breast and other women’s cancer research.
The program shares resources, creating core research facilities that enable the scientists to accelerate research. These core resources include:
- Comparative Medicine (vivarium)
- Flow Cytometry Core
- Genomics Core
- Microscopy Core
- Molecular and Micro-Imaging Core
- Mouse Genetics Core
- Imaging Core
- Biostatistics Core
- Pathology Core
- Clinical Research Office Core
In addition, the Women’s Cancer Program’s tissue bank is one of the world’s most comprehensive inventories of malignant and nonmalignant gynecologic and breast tissues. Over 100,000 specimens are now available for researchers. This resource is fundamental to the program’s ability to conduct research related to treating and diagnosing cancer, and to improving screening techniques.
The Gilda Radner Hereditary Cancer Program collects DNA along with detailed epidemiologic and clinical data on high risk women with BRCA mutations. This data is also shared with international consortia that are working to identify improved predictors of risk.